腎置換療法の選択のための共有意思決定の導入が、生物ドナー腎移植の特徴に及ぼす影響

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 


 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/20e7c5102094f32af6160fe5af50e1d1.pdf
腎置換療法の選択のための共有意思決定の導入が、生物ドナー腎移植の特徴に及ぼす影響

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
アキト
もち月
Akito Mochizuki akito.5810@icloud.com Fukuoka University Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine Fukuoka Japan *
Kazuhiro Tada ktada@fukuoka-u.ac.jp Fukuoka University Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine Fukuoka Japan -
Sho Shimamoto s.shimamoto.qu@adm.fukuoka-u.ac.jp Fukuoka University Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine Fukuoka Japan -
Koji Takahashi takahashi_k@fukuoka-u.ac.jp Fukuoka University Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine Fukuoka Japan -
Kenji Ito kito@fukuoka-u.ac.jp Fukuoka University Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine Fukuoka Japan -
Yoko Yokoyama yokonagakui@adm.fukuoka-u.ac.jp Fukuoka University Hospital Department of Nursing Fukuoka Japan -
Nobuyuki Nakamura nobu0149@fukuoka-u.ac.jp Fukuoka University Department of Urology and Nephrology, Faculty of Medicine Fukuoka Japan -
Nobuhiro Haga nhaga@fukuoka-u.ac.jp Fukuoka University Department of Urology and Nephrology, Faculty of Medicine Fukuoka Japan -
Kosuke Masutani kmasutani@fukuoka-u.ac.jp Fukuoka University Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine Fukuoka Japan -
 
 
 
 
 
 

Limited information is available regarding the impact of shared decision-making (SDM) in selecting renal replacement therapy on the clinical characteristics of living-donor kidney transplantation.

In 2019, our institution established a shared decision-making outpatient clinic (SDM clinic) for renal replacement therapy selection. We analyzed 65 cases of living-donor kidney transplantation performed between 2010 and 2025, dividing them into two groups: pre-SDM (2010–2018, n=25) and post-SDM (2019–2025, n=40). We compared donor and recipient clinical characteristics and transplantation-related factors such as ABO-incompatible kidney transplantation (ABOi-KT), the frequency of preemptive kidney transplantation (PEKT), and, among PEKT cases, estimated glomerular filtration rate (eGFR) at the start of evaluation and preoperatively, as well as the rate of preoperative dialysis.

Compared with the pre-SDM group, the post-SDM group had older donors (median age [IQR]: 55.0 [44.5–60.0] vs. 62.0 [52.3–68.0] years, P<0.05) and a higher frequency of ABOi-KT (4.0% vs. 37.5%, P<0.05). Although the overall frequency of PEKT did not significantly differ between groups, among PEKT cases, both the initial and preoperative eGFR levels were significantly higher in the post-SDM group (initial: 7.4 [6.0–8.4] vs. 11.4 [9.2–13.8] mL/min/1.73m², P<0.05; preoperative: 5.0 [4.2–6.9] vs. 8.7 [6.3–10.6] mL/min/1.73m², P<0.01), and the rate of preoperative hemodialysis was significantly lower (54.6% vs. 20.0%, P<0.05). No significant differences were observed in the frequency of post-transplant complications or graft survival between groups. 

The implementation of SDM in selecting renal replacement therapy appears to expand the indications for kidney transplantation, including the acceptance of older donors and ABO-incompatible transplants. In PEKT cases, SDM facilitates safer and more structured transplantation through earlier evaluation.

Kewords